Idiopathic Pulmonary fibrosis (IPF) is a subset of interstitial lung diseases, where in the normal ageing of lung is augmented. It is characterised by fibrosis of the lung architecture which ...

Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, and often fatal lung disease characterized by the scarring (fibrosis) of lung tissue, ...

Discover the connection between genetic risk factors for idiopathic pulmonary fibrosis and the development of post-COVID-19 ...

Researchers reveal how targeting HIF2 could transform the treatment of idiopathic pulmonary fibrosis (IPF), offering hope for ...

Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.

Management said the new name, logo, website and branding elements ... The biotech’s lead drug candidate is a potential treatment for idiopathic pulmonary fibrosis (IPF) that it picked up through ...

Pulmonary fibrosis is a rare, chronic disease that causes scarring in the lungs, making breathing difficult for people who suffer with it.

Idiopathic pulmonary fibrosis (IPF) and diabetes mellitus do not appear to have a causal association, according to study findings published in Thorax.

Pulmonary fibrosis in patients with COVID-19 tends to resolve, while idiopathic pulmonary fibrosis always progresses.